Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Needham Maintains Buy on Accolade, Raises Price Target to $15

Needham Maintains Buy on Accolade, Raises Price Target to $15

Needham analyst Ryan MacDonald maintains Accolade (NASDAQ:ACCD) with a Buy and raises the price target from $12 to $15.

byBenzinga Newsdesk

October 4, 2022

1 minute read

Needham analyst Ryan MacDonald maintains Accolade (NASDAQ:ACCD) with a Buy and raises the price target from $12 to $15.

Over $21 Million Bet On Autoliv? 3 Stocks Insiders Are Buying

By Lisa Levin

August 26, 11:33 AM

Although US stocks traded sharply lower on Friday, there were a few notable insider trades.

ALV

SAIC Raises 2024 Outlook Despite Revenue Dip: What You Need to Know?

By Anusuya Lahiri

September 7, 9:43 AM

Science Applications International Corp (NYSE: SAIC) reported a 3% revenue decline Y/Y in Q2 FY24 to $1.78 billion, beating the

SAIC

Keytruda, Gardasil Boost Merck’s Q2 Revenues, Tightens Annual Guidance

By Vandana Singh

July 28, 7:47 AM

Merck & Co Inc’s (NYSE: MRK) Q2 sales reached $14.60 billion, +28% Y/Y, beating the consensus of $13.87 billion. Excluding the…

MRK

‘Transformative Event’ For First Wave BioPharma: License Agreement for Hopeful Gastrointestinal Candidate From Sanofi

By Vandana Singh

September 14, 6:00 AM

First Wave BioPharma Inc (NASDAQ: FWBI) announced an agreement with Sanofi SA (NASDAQ: SNY) to license Capeserod, a selective 5-HT4 receptor partial agonist, which First Wave will repurpose and develop for

FWBI

Needham Maintains Buy on Accolade, Raises Price Target to $15

Related Posts

Over $21 Million Bet On Autoliv? 3 Stocks Insiders Are Buying

SAIC Raises 2024 Outlook Despite Revenue Dip: What You Need to Know?

Keytruda, Gardasil Boost Merck’s Q2 Revenues, Tightens Annual Guidance

‘Transformative Event’ For First Wave BioPharma: License Agreement for Hopeful Gastrointestinal Candidate From Sanofi